Fluorodeoxyglucose PET/Computed Tomography in Multimodality and Theranostic Workflows.
Authors
Affiliations (2)
Affiliations (2)
- Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, 110029, India. Electronic address: [email protected].
- Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, 110029, India.
Abstract
Theranostics, the integration of diagnostic imaging and targeted radionuclide therapy, has transformed oncological practice. While receptor-targeted tracers such as somatostatin receptor PET/computed tomography (CT) and prostate-specific membrane antigen PET/CT anchor most theranostic workflows, 18F-fluorodeoxyglucose (FDG) PET/CT retains an indispensable role across the spectrum of theranostic diseases. FDG PET images glucose metabolism and thereby captures biological information that receptor-targeted tracers cannot. This review synthesizes current evidence, guideline recommendations, and emerging applications, including total-body PET, AI-assisted quantification, radiomics, and novel fibroblast activation protein inhibitor targeted theranostics, to define the evolving position of FDG-PET/CT as a gatekeeper in the theranostic oncological workflow.